Morepen Laboratories Gains 11.37%: 5 Key Factors Driving the Week’s Momentum

23 February 2026: Breakout Day with Exceptional Volume and Price Surge

Morepen Laboratories began the week with a remarkable rally, opening with a gap-up of 12.85% and closing the day at Rs.45.37, a 15.42% gain from the previous close. The stock reached an intraday high of Rs.45.33, surging 15.55% intraday, driven by a massive traded volume of 1.91 crore shares valued at approximately ₹8385.08 lakhs. This volume spike was accompanied by a delivery volume increase of 122.12% compared to the five-day average, signalling strong accumulation rather than speculative trading.

The stock outperformed the Pharmaceuticals & Biotechnology sector by 14.22% and the Sensex by 12.54%, reflecting robust investor interest. Technically, the price moved above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating short- to medium-term bullish momentum, although it remained below the 200-day average, suggesting longer-term resistance.

Despite the strong price action, the weighted average price was closer to the day’s low, hinting at some profit-taking near the peak. The stock’s high beta of 1.73 contributed to elevated intraday volatility of 69.57%, consistent with its sensitivity to market movements.

24 February 2026: Continued Rally with Record Volumes Amid Valuation Reassessment

On 24 February, Morepen Laboratories sustained its upward momentum, closing at Rs.46.42, a 2.31% gain on the day and a cumulative three-day gain of 25.93%. The stock recorded an extraordinary traded volume of 2.97 crore shares, worth approximately ₹141.9 crores, positioning it among the highest volume gainers of the day. Delivery volumes soared to 1.4 crore shares, a staggering 2,079.81% increase over the five-day average, underscoring strong investor confidence and accumulation.

Morepen outperformed its sector, which declined 0.25%, and the Sensex, which fell 0.89%, highlighting its resilience amid a broadly negative market backdrop. The stock traded above its 5-day, 20-day, 50-day, and 100-day moving averages, reinforcing a positive short-term trend, though it remained below the 200-day average.

However, this price surge coincided with a shift in valuation metrics. The company’s P/E ratio rose to 32.60, pushing its valuation grade from fair to expensive. Other multiples such as EV to EBIT (26.63) and EV to EBITDA (17.87) also reflected a premium valuation relative to historical averages and some peers. While Morepen’s valuation is elevated, it remains below the most expensive sector peers like J B Chemicals and Ajanta Pharma.

25 February 2026: Profit Booking Leads to Price Correction

Following two days of strong gains, Morepen Laboratories experienced a correction on 25 February, closing at Rs.44.14, down 4.91% from the previous day. The volume dropped sharply to 9.53 lakh shares, indicating reduced trading activity. Despite the decline, the stock still outperformed the Sensex, which rose 0.41% that day, as the correction appeared to be profit-taking rather than a reversal of trend.

Technically, the stock remained above its short-term moving averages, suggesting that the correction was a healthy consolidation within an ongoing uptrend. The broader market context was mixed, with the Sensex showing modest gains but sectoral pressures persisting.

26 February 2026: Modest Recovery Amid Lower Volumes

On 26 February, Morepen Laboratories recovered slightly, closing at Rs.44.70, a 1.27% gain. Trading volumes declined further to 4.83 lakh shares, reflecting cautious investor participation. The Sensex also advanced modestly by 0.19%, supporting a mild positive market environment.

The stock’s price remained above key short-term moving averages, maintaining the technical momentum established earlier in the week. However, the low volume suggests that investors were awaiting clearer signals before committing further capital.

27 February 2026: Week Closes with Slight Decline Amid Market Weakness

The week ended with Morepen Laboratories closing at Rs.43.78, down 2.06% on the day, on volume of 4.23 lakh shares. The Sensex declined 1.16%, reflecting broader market weakness. Despite the day’s decline, the stock’s weekly gain of 11.37% represents a strong outperformance versus the Sensex’s 0.96% loss.

Technical indicators showed a nuanced picture: weekly MACD was mildly bullish, while monthly MACD remained bearish. The Relative Strength Index (RSI) hovered in neutral territory, and Bollinger Bands suggested mild bearishness on longer timeframes. These mixed signals indicate that while short-term momentum is positive, longer-term trends remain uncertain.

Weekly Price Performance Comparison

Key Takeaways

Positive Signals: Morepen Laboratories demonstrated strong price appreciation of 11.37% over the week, significantly outperforming the Sensex’s 0.96% decline. Exceptional volume surges and rising delivery volumes indicate robust accumulation by investors. The stock’s price trading above multiple short- and medium-term moving averages signals positive momentum. The mojo rating upgrade from Strong Sell to Sell reflects some improvement in fundamentals or sentiment.

Cautionary Notes: Despite short-term strength, the stock remains below its 200-day moving average, indicating unresolved longer-term resistance. Valuation multiples have shifted into expensive territory, with a P/E of 32.60 and elevated EV multiples, which may limit upside without corresponding earnings growth. Technical indicators present mixed signals, with monthly MACD and momentum oscillators remaining bearish. The stock’s high beta and intraday volatility suggest potential for sharp price swings, warranting careful risk management.

Conclusion

Morepen Laboratories Ltd’s week was characterised by a strong rally supported by exceptional trading volumes and a partial upgrade in mojo rating, signalling renewed investor interest. The stock’s outperformance relative to the Sensex and sector peers highlights its current momentum. However, the shift to expensive valuation metrics and mixed technical signals counsel prudence. Investors should monitor whether the stock can sustain its momentum and break above key longer-term resistance levels, while remaining mindful of the inherent volatility and sector-specific risks. Overall, the week’s developments present a complex but cautiously optimistic picture for Morepen Laboratories.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today